Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.46 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALPG | P10696 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3192750 | 0.89 | GPR35 (0.57) | GPR35TSHRSMN1; SMN2PDE7AMAPT | |
| SCHEMBL8734150 | 0.86 | PDE7A (0.51) | SMN1; SMN2PDE7APDE7BHSP90AA1MAPT | |
| SCHEMBL9709555 | 0.85 | PDE7A (0.58) | GPR35TSHRSMN1; SMN2PDE7APDE7B | |
| SCHEMBL27271638 | 0.82 | HSD17B10 (0.55) | GPR35TSHRSMN1; SMN2PDE7APDE7B | |
| SCHEMBL6930370 | 0.78 | PDE7A (0.59) | GPR35TSHRSMN1; SMN2PDE7APDE7B | |
| SCHEMBL1713219 | 0.77 | PDE7A (0.65) | SMN1; SMN2PDE7APDE7BMAPTALDH1A1 | |
| SCHEMBL30338244 | 0.77 | PDE7A (0.65) | SMN1; SMN2PDE7APDE7BMAPTALDH1A1 | |
| SCHEMBL224666 | 0.76 | PDE7A (0.60) | GPR35TSHRSMN1; SMN2PDE7AMAPT | |
| SCHEMBL3192742 | 0.75 | GPR35 (0.53) | GPR35TSHRSMN1; SMN2PDE7AMAPT | |
| SCHEMBL2588026 | 0.75 | GPR35 (0.58) | GPR35TSHRSMN1; SMN2PDE7AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015402-B1 | Method for producing compounds containing fluorine, in particular fluorobenzaldehydes and fluorobenzonitriles | CLARIANT GMBH (DE) | 2002-12-04 | — | — | EP | claimed |
| EP-1015402-A1 | METHOD FOR PRODUCING COMPOUNDS CONTAINING FLUORINE, IN PARTICULAR FLUOROBENZALDHYDES AND FLUOROBENZONITRILES | Aventis Research & Technologies GmbH & Co. KG (DE) | 2000-07-05 | — | — | EP | claimed |
| WO-1999011588-A1 | METHOD FOR PRODUCING COMPOUNDS CONTAINING FLUORINE, IN PARTICULAR FLUOROBENZALDHYDES AND FLUOROBENZONITRILES | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1999-03-11 | — | — | WO | claimed |
| CN-108295252-B | Method for preparing rabies combined vaccine | 成都安特金生物技术有限公司 | 2020-05-01 | — | — | CN | disclosed |
| CN-108175855-B | Rabies immunogenic conjugate | 成都安特金生物技术有限公司 | 2020-05-01 | — | — | CN | disclosed |
| CN-108187038-B | Rabies combined vaccine | 成都安特金生物技术有限公司 | 2020-05-01 | — | — | CN | disclosed |
| US-9233921-B2 | Potent poxvirus inhibitor | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-01-12 | — | — | US | disclosed |
| US-20140343114-A1 | Potent poxvirus inhibitor | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-11-20 | — | — | US | disclosed |
| EP-1015402-B1 | Method for producing compounds containing fluorine, in particular fluorobenzaldehydes and fluorobenzonitriles | CLARIANT GMBH (DE) | 2002-12-04 | — | — | EP | disclosed |
| EP-1015402-A1 | METHOD FOR PRODUCING COMPOUNDS CONTAINING FLUORINE, IN PARTICULAR FLUOROBENZALDHYDES AND FLUOROBENZONITRILES | Aventis Research & Technologies GmbH & Co. KG (DE) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999011588-A1 | METHOD FOR PRODUCING COMPOUNDS CONTAINING FLUORINE, IN PARTICULAR FLUOROBENZALDHYDES AND FLUOROBENZONITRILES | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1999-03-11 | — | — | WO | disclosed |
| EP-0093363-B1 | PROCESS FOR THE PREPARATION OF DISULPHIDES | CASSELLA Aktiengesellschaft (DE) | 1987-01-14 | — | — | EP | disclosed |
| EP-0093363-A1 | Process for the preparation of disulphides | CASSELLA Aktiengesellschaft (DE) | 1983-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343114-A1 | Potent poxvirus inhibitor | MAVS, VAC14, GZMB | GPR35 4589/4885TSHR 4492/4885SMN1; SMN2 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.